News

bit.bio Chairman Lord David Prior speaks with EMJ at the Human Cell Forum about the future of the NHS, cell therapies, and human-c...

bit.bio launches new media kits for human iPSC-derived ioCells designed to make human cell-based research significantly more acces...

bit.bio CEO Emma Pepperell joins TechRound to discuss why reliable healthcare must start with consistent, reproducible science in ...

New human iPSC-derived hepatocyte model engineered for predictive reproducibility, chronic toxicity studies, and enhanced clinical...

bit.bio appoints Dr Emma Pepperell as Chief Executive Officer

bit.bio outlines a transformative vision for drug discovery at The Human Cell Forum, emphasising the need for human cell-based mod...

bit.bio lowers ioCells pricing and opens EU hub with next-day delivery, expanding global access to human cells for NAMs research.

bit.bio, Cambridge-based pioneer in next-generation human cell programming, has successfully closed a $50 million Series C funding...